Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Short term Debt (2019 - 2026)

OptimizeRx's Short term Debt history spans 5 years, with the latest figure at $4.3 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 112.75% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a 112.75% increase, with the full-year FY2025 number at $4.3 million, up 112.75% from a year prior.
  • Short term Debt hit $4.3 million in Q4 2025 for OptimizeRx, up from $3.3 million in the prior quarter.
  • Over the last five years, Short term Debt for OPRX hit a ceiling of $4.3 million in Q4 2025 and a floor of $2.0 million in Q4 2023.
  • Historically, Short term Debt has averaged $3.0 million across 3 years, with a median of $3.3 million in 2024.
  • The widest YoY moves for Short term Debt: up 112.75% in 2025, down 5.71% in 2025.
  • Tracing OPRX's Short term Debt over 3 years: stood at $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then soared by 112.75% to $4.3 million in 2025.
  • Business Quant data shows Short term Debt for OPRX at $4.3 million in Q4 2025, $3.3 million in Q3 2025, and $3.3 million in Q2 2025.